Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 27 articles:
HTML format
Text format



Single Articles


    April 2017
  1. REN YQ, Wang HJ, Zhang YQ, Liu YB, et al
    WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
    Cancer Chemother Pharmacol. 2017 Apr 8. doi: 10.1007/s00280-017-3302.
    PubMed     Text format     Abstract available


    March 2017
  2. CHE J, Huang Y, Xu C, Zhang P, et al
    Increased ceramide production sensitizes breast cancer cell response to chemotherapy.
    Cancer Chemother Pharmacol. 2017 Mar 29. doi: 10.1007/s00280-017-3292.
    PubMed     Text format     Abstract available


  3. ROCCA A, Cecconetto L, Passardi A, Melegari E, et al
    Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3279.
    PubMed     Text format     Abstract available


  4. TANDIA M, Mhiri A, Paule B, Saffroy R, et al
    Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3268.
    PubMed     Text format     Abstract available


    February 2017
  5. WANG Z, Chen J, Zhong MZ, Huang J, et al
    Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
    Cancer Chemother Pharmacol. 2017 Feb 27. doi: 10.1007/s00280-017-3248.
    PubMed     Text format     Abstract available


  6. KONG X
    Reply to: comment on "Meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer".
    Cancer Chemother Pharmacol. 2017 Feb 22. doi: 10.1007/s00280-016-3230.
    PubMed     Text format    


    January 2017
  7. QUARTINO AL, Li H, Jin JY, Wada DR, et al
    Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
    Cancer Chemother Pharmacol. 2017 Jan 10. doi: 10.1007/s00280-016-3218.
    PubMed     Text format     Abstract available


  8. ZHANG HY, Liang F, Zhang JW, Wang F, et al
    Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3208.
    PubMed     Text format     Abstract available


  9. CARGNIN S, Terrazzino S
    Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3229.
    PubMed     Text format    


    October 2016
  10. KONG X, Li Z, Li X
    GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  11. SONG JG, Lee YS, Park JA, Lee EH, et al
    Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  12. PARK JH, Kang MJ, Ahn JH, Kim JE, et al
    Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afte
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  13. ZHANG X, Bai W
    Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  14. LI C, Wang B, Lu D, Jin JY, et al
    Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  15. YOSHITOMI S, Taira N, Doihara H, Mizoo T, et al
    A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  16. KONIG M, von Hagens C, Hoth S, Baumann I, et al
    Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format    


  17. FARHAT F, Kattan JG, Ghosn M
    Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  18. ZHAO F, Ming J, Zhou Y, Fan L, et al
    Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  19. KONIG M, von Hagens C, Hoth S, Baumann I, et al
    Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  20. LI F, Dou J, Wei L, Li S, et al
    The selective estrogen receptor modulators in breast cancer prevention.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  21. PERROUD HA, Alasino CM, Rico MJ, Mainetti LE, et al
    Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  22. QUARTINO AL, Hillenbach C, Li J, Li H, et al
    Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  23. AL-TWEIGERI T, AlSayed A, Alawadi S, Ibrahim M, et al
    A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  24. LEE O, Ivancic D, Allu S, Shidfar A, et al
    Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  25. LOPUS M, Smiyun G, Miller H, Oroudjev E, et al
    Mechanism of action of ixabepilone and its interactions with the betaIII-tubulin isotype.
    Cancer Chemother Pharmacol. 2015;76:1013-24.
    PubMed     Text format     Abstract available


  26. MORGAN RJ, Synold TW, Longmate JA, Quinn DI, et al
    Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Cancer Chemother Pharmacol. 2015;76:897-907.
    PubMed     Text format     Abstract available


    October 2015
  27. BOL GM, Khan R, Heerma van Voss MR, Tantravedi S, et al
    PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.
    Cancer Chemother Pharmacol. 2015;76:821-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: